Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
3.70
Dollar change
+0.10
Percentage change
2.78
%
Index- P/E- EPS (ttm)-3.79 Insider Own10.30% Shs Outstand2.00M Perf Week-23.50%
Market Cap7.40M Forward P/E- EPS next Y-2.09 Insider Trans0.00% Shs Float1.79M Perf Month10.94%
Income-7.01M PEG- EPS next Q-0.76 Inst Own23.95% Short Float0.10% Perf Quarter68.95%
Sales0.00M P/S- EPS this Y31.86% Inst Trans- Short Ratio0.03 Perf Half Y-40.42%
Book/sh3.04 P/B1.22 EPS next Y34.79% ROA-79.95% Short Interest0.00M Perf Year-17.16%
Cash/sh2.54 P/C1.46 EPS next 5Y- ROE-100.97% 52W Range1.98 - 8.01 Perf YTD60.17%
Dividend Est.- P/FCF- EPS past 5Y0.28% ROI-115.12% 52W High-53.81% Beta-
Dividend TTM- Quick Ratio9.44 Sales past 5Y0.00% Gross Margin- 52W Low86.87% ATR (14)0.62
Dividend Ex-Date- Current Ratio9.44 EPS Y/Y TTM-363.32% Oper. Margin0.00% RSI (14)46.77 Volatility13.80% 18.52%
Employees- Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price12.15
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q19.52% Payout- Rel Volume0.41 Prev Close3.60
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsNov 15 BMO Avg Volume65.91K Price3.70
SMA20-17.51% SMA5014.69% SMA200-9.79% Trades Volume27,272 Change2.78%
Mar-27-24 05:00AM
Mar-19-24 09:30AM
05:00AM
Mar-11-24 07:00AM
Mar-04-24 07:00AM
07:00AM Loading…
Feb-15-24 07:00AM
Feb-01-24 08:46PM
Jan-15-24 07:00AM
Jan-03-24 07:00AM
Jan-02-24 07:00AM
Nov-30-23 07:30AM
Nov-29-23 07:00AM
Nov-10-23 07:00AM
Nov-08-23 05:00PM
Nov-02-23 07:00AM
05:30PM Loading…
Oct-27-23 05:30PM
Oct-25-23 05:00PM
07:00AM
Oct-23-23 09:10AM
Oct-20-23 08:42AM
Oct-12-23 07:00AM
Oct-04-23 07:00AM
Sep-28-23 07:00AM
Sep-11-23 07:00AM
Sep-07-23 07:00AM
Aug-29-23 07:00AM
Aug-04-23 05:00PM
Jun-29-23 08:00AM
Jun-23-23 08:51PM
Jun-06-23 07:00AM
07:00AM Loading…
May-24-23 07:00AM
May-04-23 07:00AM
Apr-21-23 07:00AM
Mar-14-23 07:00AM
Feb-07-23 07:00AM
Feb-01-23 07:00AM
Jan-19-23 07:00AM
Jan-03-23 07:00AM
Dec-19-22 07:00AM
Dec-08-22 07:00AM
Nov-28-22 07:00AM
Nov-25-22 05:45PM
Nov-16-22 07:00AM
Nov-08-22 03:40PM
Nov-03-22 05:00PM
10:15AM
Oct-26-22 07:00AM
Oct-25-22 07:00AM
Oct-07-22 06:02PM
Oct-04-22 08:30AM
Sep-19-22 07:00AM
Sep-01-22 07:00AM
Aug-22-22 07:00AM
Aug-04-22 07:00AM
Jul-22-22 08:00AM
Jul-19-22 07:00AM
Jul-13-22 07:00AM
Jul-07-22 07:00AM
Jun-21-22 07:00AM
Jun-13-22 08:55AM
Jun-08-22 07:00AM
Jun-06-22 07:00AM
May-25-22 08:00AM
May-05-22 07:00AM
May-03-22 07:00AM
Apr-20-22 07:00AM
Apr-12-22 07:00AM
Apr-07-22 07:00AM
Mar-31-22 07:00AM
Mar-23-22 07:00AM
Mar-14-22 07:00AM
Jan-31-22 07:00AM
Jan-20-22 07:00AM
Jan-12-22 08:30AM
Jan-10-22 07:00AM
Dec-22-21 08:30AM
Dec-21-21 06:00PM
07:00AM
Dec-10-21 07:01AM
Dec-09-21 11:53AM
09:30AM
08:04AM
Dec-02-21 07:00AM
Nov-23-21 07:00AM
Nov-15-21 08:00AM
Nov-09-21 07:00AM
Nov-05-21 08:11AM
Nov-04-21 02:49PM
08:21AM
Nov-02-21 06:13PM
Oct-15-21 05:38PM
Oct-14-21 05:30PM
07:00AM
XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.